Cytek Biosciences, Inc. (CTKB) Misses Q3 EPS by 1c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts CTKB Hot Sheet
Join SI Premium – FREE
Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $52.3 million versus the consensus estimate of $51.03 million.
For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s posts better-than-expected third-quarter comparable sales
- SelectQuote, Inc. (SLQT) Tops Q1 EPS by 13c ; Offers Guidance
- Shoals Technologies Group, Inc. (SHLS) Tops Q3 EPS by 2c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
